"We have finally transitioned our old business operation to the biopharmaceutical business operation in China. It is a right time to change our name. This proposed new name would be more accurate ly reflect our current business operation, as we are a leading developer, producer and distributor of vaccine products in China. We are ready to distribute flu vaccines as the flu season in China is fast approaching," Peter Wang, CEO of Techedge Inc. stated.

For more information, please go to http://www.otcreporter.com

To read the complete release, go to http://www.CybeRelease.com/tedg7606.htm

Other active stocks are Millicom International Cellular S.A. (NASDAQ: MICC), Helen of Troy Limited (NASDAQ: HELE) and Lifecore Biomedical, Inc. (NASDAQ: LCBM).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A Third Party has hired and paid $500.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.